AbbVie Inc., a leading pharmaceutical company, is valued at $405.6 billion. Known for its immunology and oncology products like Imbruvica and Rinvoq, ABBV invests heavily in research and development, maintaining a robust pipeline of innovative therapies. Despite a recent dip, ABBV stock outperformed the Nasdaq Composite.

In the past year, ABBV shares rose 30.9%, surpassing NASX’s gains. The company’s strategic acquisitions and focus on immunology and neuroscience have propelled its growth. With investments in manufacturing and advancements in pipeline programs, ABBV remains a strong player in the industry.

ABBV reported its Q3 results, with adjusted EPS exceeding expectations at $1.86 and revenue hitting $15.8 billion. Despite a 4.5% drop in shares, ABBV remains optimistic, expecting full-year adjusted EPS between $10.61 to $10.65. Analysts are bullish on ABBV’s future, with a consensus “Moderate Buy” rating and a mean price target of $244.54.

Read more at Yahoo Finance: Is AbbVie Stock Outperforming the Nasdaq?